title: HIV treatment for prevention.
abstract: "No virus, no transmission." Studies have repeatedly shown that viral load (the quantity of virus present in blood and sexual secretions) is the strongest predictor of HIV transmission during unprotected sex or transmission from infected mother to child. Effective treatment lowers viral load to undetectable levels. If one could identify and treat all HIV-infected people immediately after infection, the HIV/AIDS epidemic would eventually disappear.Such a radical solution is currently unrealistic. In reality, not all people get tested, especially when they fear stigma and discrimination. Thus, not all HIV-infected individuals are known. Of those HIV-positive individuals for whom the diagnosis is known, not all of them have access to therapy, agree to be treated, or are taking therapy effectively. Some on effective treatment will stop, and in others, the development of resistance will lead to treatment failure. Furthermore, resources are limited: should we provide drugs to asymptomatic HIV-infected individuals without indication for treatment according to guidelines in order to prevent HIV transmission at the risk of diverting funding from sick patients in urgent need? In fact, the preventive potential of anti-HIV drugs is unknown. Modellers have tried to fill the gap, but models differ depending on assumptions that are strongly debated. Further, indications for antiretroviral treatments expand; in places like Vancouver and San Francisco, the majority of HIV-positive individuals are now under treatment, and the incidence of new HIV infections has recently fallen. However, correlation does not necessarily imply causation. Finally, studies in couples where one partner is HIV-infected also appear to show that treatment reduces the risk of transmission.More definite studies, where a number of communities are randomized to either receive the "test-and-treat" approach or continue as before, are now in evaluation by funding agencies. Repeated waves of testing would precisely measure the incidence of HIV infection. Such trials face formidable logistical, practical and ethical obstacles. However, without definitive data, the intuitive appeal of "test-and-treat" is unlikely to translate into action on a global scale. In the meantime, based on the available evidence, we must strive to provide treatment to all those in medical need under the current medical guidelines. This will lead to a decrease in HIV transmission while "test-and-treat" is fully explored in prospective clinical trials.
authors: HIV Unit, Department of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland.
authors: Juan
authors: J
authors: Ambrosioni
authors: Alexandra
authors: A
authors: Calmy
authors: Bernard
authors: B
authors: Hirschel
references: N Engl J Med. 1994 Nov 3;331(18):1173-80
references: 7935654
references: Clin Infect Dis. 2004 Apr 15;38(8):1167-74
references: 15095224
references: PLoS Med. 2005 Nov;2(11):e298
references: 16231970
references: AIDS. 2008 May 31;22(9):1071-7
references: 18520351
references: JAMA. 2010 Jul 21;304(3):321-33
references: 20639566
references: PLoS Med. 2007 Dec;4(12):e343
references: 18052604
references: AIDS Educ Prev. 2010 Apr;22(2):126-37
references: 20387983
references: Science. 2010 Sep 3;329(5996):1168-74
references: 20643915
references: AIDS. 2008 Nov 30;22(18):2509-15
references: 19005274
references: Am J Public Health. 2010 Oct;100(10):1867-76
references: 20724682
references: AIDS. 2009 Jul 17;23(11):1415-23
references: 19487906
references: AIDS. 2008 Nov 12;22(17):2303-11
references: 18981769
references: PLoS One. 2010 Jun 10;5(6):e11068
references: 20548786
references: BMJ. 2009 Apr 30;338:b1649
references: 19406887
references: Lancet. 2008 May 10;371(9624):1603-11
references: 18468544
references: J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94
references: 11981365
references: AIDS. 2000 Jan 28;14(2):117-21
references: 10708281
references: Lancet. 2010 Aug 14;376(9740):532-9
references: 20638713
references: AIDS. 2010 Jan;24 Suppl 1:S37-44
references: 20023438
references: Lancet. 2008 Mar 1;371(9614):752-9
references: 18313504
references: Lancet. 2010 Jun 12;375(9731):2092-8
references: 20537376
references: Antivir Ther. 2008;13(5):729-32
references: 18771057
references: Arch Intern Med. 1994 Sep 12;154(17):1971-6
references: 8074601
references: PLoS One. 2010 Jun 07;5(6):e10991
references: 20539817
references: Lancet. 2007 Feb 24;369(9562):657-66
references: 17321311
references: Arch Intern Med. 2010 Aug 9;170(15):1347-54
references: 20696960
references: Lancet. 2009 Jan 3;373(9657):48-57
references: 19038438
references: AIDS. 1998 Jul 9;12(10):F91-5
references: 9677158
references: Antivir Ther. 2008;13(2):177-87
references: 18505169
references: BMJ. 2010 May 14;340:c2205
references: 20472675
references: New Microbiol. 2008 Jan;31(1):19-26
references: 18437838
references: Lancet. 2006 Mar 11;367(9513):817-24
references: 16530575
references: Lancet. 2007 Feb 24;369(9562):643-56
references: 17321310
references: Lancet. 2006 Aug 5;368(9534):531-6
references: 16890841
references: N Engl J Med. 2000 Mar 30;342(13):921-9
references: 10738050
references: Lancet. 2008 Jul 26;372(9635):314-20
references: 18657710
references: PLoS One. 2008 Apr 23;3(4):e2021
references: 18431498
references: AIDS. 2010 Jul 31;24(12):1929-35
references: 20588171
references: AIDS. 2000 Mar 10;14(4):415-21
references: 10770544